Popular Topics
All Topics
- "Gun Jumping"
- "Test-the-Waters" communications
- 10b5-1 plans
- 2016 SEC Agenda
- ABL
- Accelerated Filer
- Accelerated filers
- Access to Capital and Market Liquidity Report
- Accounting
- Accredited investor
- Advance Notice Bylaws
- Airbnb
- Alternative Trading Systems
- Amended Rule 15c2-11
- Annual meeting
- Annual reports
- ASC Topic 740
- Asset Management
- asset-based loan
- ATS
- Auction IPOs
- Audit committee
- Auditor attestation
- Authentication document
- Bankruptcy
- Blackout periods
- BlackRock
- Blank-check companies
- Blockchain
- blue sky
- Board committees
- Board Diversity
- Board independence
- Board of Directors
- Boilerplate
- Boilerplate in securities documents
- borrower
- Broker-dealer
- Broker-dealer registration
- Broker-dealers
- Business organizations
- Calculation of Registration Fee
- California
- California Assembly Bill 979
- Capital formation
- capital markets
- Capital raising
- CARES Act
- cash management
- CEO letters
- Certified B corporation
- Chair Mary Jo White
- Chairman’s letters
- Chairperson’s letters
- changes to offering terms
- Climate Change
- coal companies
- coal company IPOs
- coal miners
- coal mining
- collateral
- collateralized mortgage-backed securities "CMBS"
- Columbia Law School
- Commencement of an offering
- Compensation sharing
- Compensatory offerings
- Compensatory sales
- Compensatory securities
- Compensatory securities offerings and sales
- Compliance and Disclosure Interpretation 110.02
- conditions precedent
- conference
- Confidential filings
- Confidential information
- Confidential treatment
- Confidentiality agreements
- coronavirus
- Corporate Governance
- Corporate Law
- Corporate social responsibility
- Corporate social responsibility: CSR
- Corporate Stock-Givaway Program
- covenants
- COVID-19
- credit agreement
- Crowdfunding
- Cryptocurrency
- CSR
- Cyber breach
- cyber incident
- Cyber risk
- Cyber-attack
- cybersecurity
- DAO
- December 31 Fiscal year end
- Decimalization
- Definition of a Security
- Delaware corporate law
- Delaware Law
- Delayed filings
- Delaying amendment
- Description of Business
- Designer stock
- Digital Advertising
- Digital securities
- Direct listings
- Direct marketing programs
- Direct response marketing
- Director Nominees
- Director Questionnaire
- Directors
- Disclosure
- Disclosure and Reporting
- Disclosure Effectiveness Initiative
- Disclosure Obligations
- Disclosure Regime
- Disclosure regulation
- Disclosure Requirements
- Disclosure Rules
- Disclosure simplification
- Disclosure updates and simplification release
- Diversity
- Division of Corporation Finance
- Dodd Frank
- Dodd-Frank Act
- Domino's Piece of the Pie Rewards
- Domino's Pizza
- Donald Trump
- Dual Class Shares
- Dual-class Capitalization
- Dual-Class Common Stock
- Dual-class shareholder voting
- Due diligence
- earnings guidance
- Economic Growth, Regulatory Relief, and Consumer Protection Act
- EDGAR Filing Manual
- EGC
- Electronic signatures
- Emerging growth companies
- Emerging Growth Company
- Employee Practices
- engagement letter
- environment, social and governance
- Environmental, Social and Governance
- Equity Market Structure
- ESG
- event of default
- events of default
- Exchange Act
- Exchange Act Rule 12b-2
- Exchange Act Rule 15c2-11
- Exchange listing
- Exchanges
- executive compensation
- Exempt offerings
- Exempt securities offerings
- Exhibits to Registration Statement
- Expert Market
- FAST Act
- FDA
- FDIC
- Federal Deposit Insurance Corporation
- Female
- Fictitious regulators
- Filing review comments
- financial forecasts
- Financial guidance
- Financial Industry Regulatory Authority
- Financial intermediaries
- Financial projections
- Financial sophistication
- Financial statements
- Financing Alternatives
- Finders
- Finders exception
- Finders exemption
- FINRA
- FINRA Rule 5130
- FINRA Rule 5131
- First-day pop
- Five-factor test
- Form 1-A
- Form 10-K
- Form 10-Q
- Form D
- Form NT
- Form S-1
- Form S-3
- Form S-4
- Forward-looking information
- Founder’s letters
- Fraud
- Fraudulent activities
- Free Stock
- Free Stock Offerings
- FTC
- General Motors Co.
- General solicitation
- general solicitation offerings
- Glass Lewis
- Global Warming
- Golden Leashes
- Greenlight Capital, Inc.
- Hart-Scott-Rodino
- HSR Act
- Impersonators of genuine firms
- Incorporation by reference
- Indications of Interest
- Influencer Marketing
- Information asymmetry
- Initial coin offering
- Initial listing requirements
- Initial public offerings
- Insider sales
- Insider Trading
- Integration
- interest
- Interest rate system
- Interest rates
- Intrastate offerings
- Investment banking
- Investment Company Act
- Investor Advisory Committee
- Investor Alert
- IPO
- IPO disclosure
- IPO drawbacks
- IPO pricing
- IPOs
- ISS
- Item 10(b)
- Item 101
- Item 103
- Item 103 of Regulation S-K
- Item 105
- Item 401 of Regulation S-K
- Item 501(b)(7)
- Item 504 of Regulations S-K
- Item 601(b)(24) of Regulation S-K
- James Mackintosh
- JOBS Act
- Jumpstart Our Business Startups Act
- Ken Langone
- known trends, demands, commitments, events or uncertainties
- Large Accelerated Filer
- Larry Fink’s 2019 letter to CEOs
- Late filings
- Law
- Legal proceedings
- lender
- LGBTQ+
- LIBOR
- line of credit
- Liquidity
- LLC
- loan agreement
- Loan Agreements
- Loan transactions
- Loans
- Loyalty Programs
- Lyft, Inc.
- MAE
- Main Street Loans
- Management
- management disclosure and analysis
- Management; Executive officers and directors
- Mark Cuban
- Material contract exhibits
- Material nonpublic information
- MD&A
- Mergers & Acquisitions
- Microcap companies
- Mini-IPO
- Missing filings
- Modernization
- Multi-Class Shares
- NASDAQ
- Nasdaq Independence Rules
- Nasdaq Listing Rules
- Nomination Letter
- Non-accelerated Filer
- Non-GAAP Financial Measures
- NSMIA
- NYSE
- Offering circular
- Offering circular supplement
- Offering fees
- Offering proceeds
- Offering statement
- Offering statement on Form 1-A
- Offering statement on Form C
- Office of the Advocate for Small Business Capital Formation
- operating capital
- Ordinary Course Covenant
- OTC
- OTC Market Group
- OTC Markets
- OTC Pink
- OTC quoted companies
- OTCQB
- Paid-for Research
- pandemic
- Pay Ratio Disclosure
- Pay Ratio Rule
- Paycheck Protection Program (PPP)
- Payroll Protection Program (PPP)
- perfection certificate
- Periodic reports
- Perpetual dual-class stock
- Power of Attorney
- Pre-established plan
- Prescriptive-based disclosure
- Primary issuances
- Principal Executive Offices
- Principles-based disclosure
- Private Equity
- Private fund knowledgeable employees
- Private placements
- Prof. John C. Coffee, Jr.
- Proposed Rule 5605(f)
- Prospectuses
- proxy advisory firms
- Proxy Contests
- Proxy fights
- Proxy materials
- Proxy statement
- Proxy voting
- Public benefit corporation
- Public Companies
- Public company acquisitions
- Public Float
- Public M&A
- Public offerings
- Pump-and-dump
- Purpose & Profit
- Purpose of the corporation
- Qualification of offering
- Qualified institutional buyer
- Ramp-and-dump
- Reference interest rates
- Reg S-K
- Registered offerings
- Registered public offerings
- Registration Filing Fee
- Registration statement
- Registration statements
- Regulation A activity
- Regulation A Offerings
- Regulation A registration exemption
- Regulation A+
- Regulation Crowdfunding
- Regulation D
- Regulation FD
- Regulation of finders
- Regulation S
- Regulation S-K
- Regulation S-K Item 10(f)(1)
- Regulation S-K Item 303
- Regulation S-T
- Regulations S-K
- Regulatory Entrepreneurship
- Release No. 34-90112
- Reporting Category
- representations
- resource extraction antigraft rule
- restricted stock
- Reverse mergers
- revolver
- Rights offerings
- Risk Factors
- Rule 10b-5
- Rule 10b5-1
- Rule 10b5-1 plan
- Rule 144A
- Rule 14a-4
- Rule 163B under the Securities Act of 1933
- Rule 21F-17
- Rule 24b-2 under the Securities Exchange Act of 1934
- Rule 253(f)
- Rule 302(b)
- Rule 4(a)(2) offering
- Rule 406 under the Securities Act of 1933
- Rule 473 under the Securities Act of 1933
- Rule 483 under the Securities Act of 1933
- Rule 504 limited offerings
- Rule 506(b)
- Rule 506(c)
- Rule 701
- S&P Dow Jones
- Safe Harbor
- Safe harbor for forward-looking information
- SAFEs
- Sarbanes-Oxley Act §404(b)
- Say-on-Pay Frequency Vote
- SEC
- SEC approval of offerings
- SEC Comments
- SEC Commissioner Robert J. Jackson Jr.
- SEC disclosure
- SEC disgorgement
- SEC Division of Economics and Risk Analysis
- SEC Filing Deadlines
- SEC Filing Reviews
- SEC Form 10
- SEC Office of Investor Education and Advocacy
- SEC Release No. 33-10591
- SEC Report of Investigation
- SEC review
- SEC Rule 152
- SEC shutdown
- Section 11(a) of the Securities Act of 1933
- Section 21F
- Section 27A of the Securities Act of 1933
- Section 8(a) of the Securities Act of 1933
- securities
- Securities & Exchange Commission
- Securities Act
- Securities Act of 1933
- Securities Act Rule 257
- Securities Act Rule 405
- Securities Act Rules 251, 252 and 253
- Securities Act Section 17(b)
- Securities Exchange Act
- Securities Exchange Act of 1934
- Securities Exchange Act Rule 12b-25
- Securities Exchange Act Section 13(a)
- Securities litigation
- Securities offerings
- securities transactions
- Severance Agreements
- Sexual harassment
- Sexual misconduct
- Shareholder Activism
- shareholder activists
- Shareholder nominations
- Shareholder rights
- Shareholder voting
- Shareholder Voting Rights
- shelter in place
- Signature Bank
- Signatures in Registration Statement
- Silicon Valley Bank
- Simple Agreement for Future Equity
- Small business
- Small businesses
- Small-cap
- Small-cap Companies
- Small-cap IPOs
- Small-cap Issuers
- Smaller reporting companies
- Smaller reporting company
- Snap IPO
- Social Capital Hedosophia
- Social Media
- Social Media Marketing
- SOFR
- SPAC
- SPAC's
- Special Purpose Acquisition Company
- Special situations
- Spin-offs
- Sponsorship
- Spotify
- SRC
- Staff Accounting Bulletin (SAB) No. 118
- Staff Comments
- Staleness date
- Startups
- State securities laws
- stock options
- Stock Ownership Guidelines
- Stock Promotion Schemes
- Strategic spin-offs
- Sunset provisions
- Supreme Court
- Sustainability
- SVB
- Switch, Inc.
- T+2
- Targeted stocks
- Tax
- Tax Cuts and Jobs Act
- Tech IPOs
- Tech M&A
- Tech unicorns
- term loan
- term sheet
- Termination or Completion of an offering
- The CLS Blue Sky Blog
- The Wall Street Journal
- Third Party Payments
- Tick Pilot
- Tick Size
- Tick Size Pilot Program
- Tick Sizes
- Token sales
- Tracking stocks
- Trade Settlement
- Trading
- trading platforms
- Transaction-based compensation
- U.S. dollar LIBOR
- U.S. federal income tax reform
- Uber Technologies, Inc.
- Underrepresented Minority
- Underwriting allocations
- Underwriting fees
- Undisclosed Fees
- Unequal Voting Rights
- Universal proxy ballots
- Unregistered finders
- Unregistered offerings
- Unregistered Soliciting Entities
- Unsolicited quotes
- Uplisting
- US Supreme Court
- Use of boilerplate
- Use of IPO proceeds
- Use of Proceeds
- venture capital
- venture capital investors
- venture capital terms
- Venture exchanges
- Verification of accredited status
- Virtual currency
- voting control
- voting power
- warranties
- Whistleblower Program
- Whistleblowers
- Window periods
- “Tandy” Representations
- “Testing the Waters”
Recent Posts
- Microcap Regulation A Issuers Targeted by the SEC for Offering Registration Violations
- Silverman and Katz Publish Article in Securities Regulation Law Journal on SEC Rulemaking and Significant Litigation for Q4 2022
- Three Lessons Learned from the Recent Bank Collapses
- SEC Issues Sample Comment Letter Regarding Crypto Risks
- SEC Sample Comment Letters – A Helpful Resource for Preparing Annual Reports and Registration Statements
- FINRA and the Stock Exchanges Take Aim at Underwriters to Address Small-Cap IPO “Ramp and Dump” Schemes
- Recent SEC Enforcement Action Provides Cautionary Guidance for Adopting and Structuring 10b5-1 Plans
- Kudos to the 2021 SEC Office of the Advocate for Small Business Capital Formation
- More than 2,000 Publicly Traded Companies Shifted to OTC’s Expert Market as Amended Rule 15c2-11 Goes into Effect
Archives
- May 2023
- March 2023
- December 2022
- November 2022
- October 2022
- February 2022
- December 2021
- October 2021
- July 2021
- April 2021
Contact Us
(212) 451-2300
www.olshanlaw.com
The Struggle to Disclose an Issuer’s Intended Uses of Proceeds in Registered Public Offerings
Investors need to understand the purposes for which an issuer’s net proceeds from a public offering are intended to be used. However, it appears lately that many issuers are routinely providing little specificity with regard to the allocation of their proposed net proceeds. Perhaps some issuers believe that the specific information required pursuant to Item 504 of Regulation S-K forces them to publicly reveal business plans that might put them at a competitive disadvantage. Even so, whether or not an issuer has a specific plan for its offering proceeds in place, there are many instances requiring special Use of Proceeds disclosure that an issuer may overlook.
The Use of Proceeds section of an offering prospectus affords investors a window into an issuer’s operational mindset and serves to drive the entire prospectus disclosure. The use of proceeds establishes management’s most important business initiatives, underpins the terms and amount of the offering, provides a snapshot of the issuer’s near-term financial condition and identifies the areas where management may need additional or specialized expertise. From there, the Use of Proceeds section addresses the risk factors involved in the issuer’s execution of its business initiatives, informs the liquidity and capital resources section of Management’s Discussion and Analysis concerning the sufficiency of the issuer’s cash to cover operating expenses for the next 12 months and, of course, is central to the cautionary note regarding the issuer’s forward-looking statements. In fact, the SEC has indicated in its comment letters that, especially in the case of an initial public offering (IPO) by a smaller issuer, the issuer should disclose whether the proceeds from the offering will be used to fund each and every element of the issuer’s growth strategy typically included in an issuer’s offering prospectus summary.
Item 504 of Regulation S-K requires an issuer to identify the principal purposes for which it plans to use the net proceeds from an offering and the approximate amount intended to be used for each of those purposes. For example, many issuers intend to use the net proceeds from their offering to fund research and product development, marketing and sales, potential acquisitions and repayment of outstanding loans.
For an issuer that is unable to specify its intended use of proceeds, it must alternatively state that it has no current specific plan for a significant portion of the offering proceeds and discuss the principal reasons for the offering at the time of the filing given this lack of a plan, and include as a risk factor its lack of a specific plan.
Despite the importance to investors of understanding the purposes for which an issuer’s net proceeds are intended to be used, it appears many issuers are routinely providing little specificity with regard to the allocation of their proposed net proceeds. Instead, the disclosure is often vague without any current specific plan included in the Use of Proceeds section, potentially qualifying the transaction as a “blind pool” under federal and state securities laws, or it is lumped into “general corporate purposes,” the most general term that companies can use in this section. Indeed, in many recent prospectuses, the Use of Proceeds section is the shortest of all substantive disclosure sections in the prospectus. And, most issuers no longer utilize the once customary Use of Proceeds table that listed each use, its respective amount and percentage of the total net proceeds, and prioritized the uses.
In a June 2021 letter from two U.S. Senators to SEC Chair Gensler and Commissioner Lee providing input on the SEC’s proposed regulation of issuers’ climate change disclosures, the Senators wrote:
The SEC can help address [climate change disclosures] by requiring greater transparency and specificity regarding use-of-proceeds declarations in prospectuses. Issuers should clearly communicate to the market what they intend to finance with the proceeds of debt or equity offerings. If the Commission permits issuers to cite “general corporate purposes” with no accountability, there can be no way of knowing whether capital will, in fact, be dedicated to the transition [to low-carbon business models]. More specificity around proceeds will also go a long way towards ensuring financial firms (whether underwriters or asset managers) are meeting their stated climate commitments.
Perhaps some issuers believe that specific information required pursuant to Item 504 of Regulation S-K forces them to publicly reveal business plans that might put them at a competitive disadvantage or they think that a lack of transparency allows them to keep more of their options open. It is unclear whether such an approach is actually benefitting those issuers. Certain academic studies, described in more detail at the end of this blog post, have suggested that more specific use of proceeds disclosure has the potential to reduce IPO underpricing for issuers and assist investors in evaluating an issuer’s prospects in the early years following their IPO.
Disclosures in Special Situations
Whether or not an issuer has a specific plan for its offering proceeds in place, there are many instances requiring special Use of Proceeds disclosure under Item 504 of Regulation S-K that an issuer may overlook. A number of special situations are described below.
Repayment of Indebtedness
If the issuer intends to use any of the net proceeds to repay outstanding indebtedness under its promissory notes, loans or credit facilities, the issuer must disclose the interest rate and maturity date of such debt pursuant to Instruction 4 to Item 504. Similarly, if an issuer expects to use a material amount of the offering proceeds to service its debt by paying only the accrued interest on the note, rather than repaying the remaining outstanding amount in full, the same disclosure is required in Use of Proceeds. Frequently, when the indebtedness is incurred within one year, such as in a pre-IPO bridge financing consisting of promissory notes, an issuer must also include a statement as to how it used the proceeds from the previously incurred debt. This requirement, however, does not include short-term borrowings used for working capital. In certain instances where issuers disclose that they have outstanding debt but do not plan to use any of the proceeds to repay it, the SEC may ask the issuer, typically one with negative working capital, to address how it intends to meet its cash needs, including debt obligations, over the next 12 months.
Drug Development and Clinical Trials
In the biotechnology space, if an issuer intends to use any of the net proceeds for clinical trials of its drug candidates, the issuer must disclose whether it will be able to complete those trials with the offering proceeds or, alternatively, how far the issuer expects to reach in the clinical development process for each of the drug candidates with the proceeds from the offering. In many instances, the biotech issuer cannot describe in greater specificity how far it expects the net proceeds from the offering to reach in the development of its drug candidates due to the uncertainty of timing for FDA marketing and other regulatory approvals, but it is nonetheless required to provide the reasons why that is the case. If the proceeds from the offering are insufficient to cover each specified purpose (which may include not only conducting trial but also clinical and development milestone payments), the issuer must state the amounts and sources of other funds needed for each specified purpose and the sources for additional funds as required by Instruction 3 to Item 504 of Regulation S-K. Additionally, the SEC has indicated in comment letters that, where the issuer is progressing with multiple drug development programs, proceeds should be allocated by individual development program, rather than disclosed in the aggregate. In some cases, issuers have aggregated their use of proceeds by stage of development or clinical phase rather than by development program, indicating that this is the appropriate allocation for investors to understand how far the funds from the offering will allow them to proceed with the continued development of their programs.
Beyond the biotechnology industry, this use of proceeds disclosure also applies to issuers in other industries that develop new products or service offerings, where capital is needed to fund discrete development projects over time.
Business Acquisitions
If the issuer intends to use any of the net proceeds from the offering to fund the acquisition costs of a specific pending or future business, the issuer must identify and describe the business, describe the material terms of the acquisition agreements, file the agreements as exhibits to the registration statement, and add risk factors to address any risks associated with the acquisition. Moreover, if the acquisition is probable at the time of the offering, the issuer must include audited historical financial statements of the business to be acquired and pro forma financial statements showing the effect of the acquisition on the issuer, pursuant to Instruction 6 to Item 504 of Regulation S-K. Under the Use of Proceeds section of the prospectus, the issuer must disclose the approximate dollar value of the amount of net proceeds expected to be used in connection with the acquisition, including a percentage breakdown of the amount for such items as earn-out cash payments, integration-related expenses and other similar matters. If the issuer intends to use the offering proceeds for acquisitions but it does not have any current plans, arrangements or agreements in place for such acquisitions, it must disclose this fact. In the extreme example of an IPO by a special purpose acquisition company (SPAC), which is specifically formed for the purpose of effecting a future business combination with one or more unidentified businesses, the usual prospectus cover page prominently states that the company has not selected any specific business combination target and it has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target.
Best-Efforts Offerings
If the public offering is structured as a best-efforts offering with minimum and maximum aggregate offering amounts, the issuer must show its use of proceeds information in multiple scenarios assuming varying levels of proceeds raised and number of shares sold in the offering pursuant to Instruction 1 to Item 504 of Regulation S-K. Typically, the disclosure would indicate the use of proceeds from the offering based on 25%, 50%, 75% and 100% of the offering being completed, with a discussion of the issuer’s priorities for the proceeds at each level. If there is a minimum amount of offering gross proceeds that must be raised to hold an initial closing for the offering, the minimum amount of the gross proceeds should also be reflected among the differing proceeds allocations.
Proceeds Benefitting Related Parties
If the issuer intends to use any of the net proceeds from the offering for a purpose that would benefit an executive officer, director or principal shareholder of the issuer, disclosure of the transaction and the total amount of the offering proceeds that such related party will receive must be included in the Use of Proceeds section of the prospectus. Examples of these transactions include the repurchase by the issuer of its shares, warrants or other securities from a related party, repayment of an issuer’s third-party indebtedness that was guaranteed by a related party and repayment of a related party for advances made in connection with the upfront expenses of the offering. Cross-references to disclosure under Certain Relationships and Related Party Transactions should be made to explain any associated conflicts of interest.
Special IPO Bonuses
If the issuer intends to use any of the net proceeds from the offering to pay a one-time bonus to an executive officer, for example, upon the closing of the issuer’s IPO if the offering size reached a certain level, the issuer must include this payment in its Use of Proceeds discussion (ideally under a separate line item, rather than working capital), as well as other sections including Executive Compensation.
Secondary Offerings for Selling Shareholders
In a secondary offering, where a resale shelf registration statement involves the sale of securities by selling shareholders, the registrant must disclose that it will not receive any of the proceeds from the offering. However, if the selling shareholders acquired their securities in a pre-IPO private placement or a PIPE offering that included warrants and would be required to exercise the warrants they received for cash prior to the sale of the underlying registered shares of common stock, the registrant must disclose the use of proceeds that it may receive from those selling shareholders who exercise their warrants.
Warrant and Option Exercise Proceeds
If the public offering includes units consisting in part of warrants to purchase common stock for cash, the issuer must disclose the use of proceeds, if any, that it may receive from those investors who exercise their warrants. Similarly, if the proceeds from an underwriter’s exercise of its over-allotment option to purchase additional shares in the offering will be used for purposes other than those already delineated for the offering, that disclosure would also be required.
Changes to the Use of Proceeds
Even if an issuer has a current specific plan for its offering proceeds, an issuer is not committed to that particular course of action and may reserve the right to change its stated use of proceeds, provided that such reservation is due to certain contingent events that are discussed specifically and the alternatives to any such uses in those events are indicated, according to Instruction 7 to Item 401 of Regulation S-K. Additionally, where the issuer indicates that it may draw funds from certain less important business objectives if more funds than estimated are required to complete more pressing objectives, the issuer needs to disclose how it will prioritize the order of the objectives for purposes of deciding from which ones to draw funds. Following an issuer’s initial registered offering, Securities Act Rule 463 and Item 701(f) of Regulation S-K require periodic disclosure of the use of offering proceeds so investors can try to follow an investor’s changed plans and priorities.
Pending the Use of Proceeds
At the bottom of the Use of Proceeds section, issuers typically indicate that pending application of the stated uses of the offering proceeds, they intend to temporarily invest the net proceeds in “short-term, interest-bearing obligations” or, in other words, “safe” investments. Investing offering proceeds in a highly leveraged hedge fund pending the use of those proceeds would normally not be considered a safe investment.
Use of Proceeds Misstatements and Litigation
In a number of recent enforcement actions, the SEC has indicated that material misstatements and misleading omissions regarding an issuer's use of offering proceeds are violations of the antifraud provisions of Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. While public companies may believe that they have the benefit of the Private Securities Litigation Reform Act's safe harbor for forward-looking statements when making their disclosures, the SEC has alleged that because the issuer knew that the statements were false when made, the issuer does not get the benefit of the safe harbor's protection. In particular, the SEC has brought complaints against issuers and executive officers relating to the failure to disclose that funds raised in the offering would be used for stock promotion activities (SEC v. GPL Ventures LLC, 1:21-cv-06814 (S.D.N.Y.)) and commissions to be paid to brokers in a Regulation A+ public offering (SEC v. Davenport, 8:21-cv-01427 (C.D. CA)), and seeking penalties to make investors whole.
. . . . .
It appears lately that many issuers are struggling with use of proceeds disclosures. Issuers are routinely providing little specificity with regard to the allocation of their proposed net proceeds. This may not necessarily be benefitting those issuers.
A number of academic studies have been conducted over the past ten years on the impact of an offering’s use of proceeds disclosure on valuation. The studies looked at use of proceeds disclosures relating to the intended uses of the proceeds (e.g., growth, production or financing) and amount committed to specific purposes. These variables were then related to IPO underpricing, survival prediction and expected and realized prospects of the IPOs. The results suggested that the use of proceeds disclosure has an incremental impact, perhaps more than any other source of information, for underpricing, for predicting firm survival and, in the case of some disclosure categories, for investors’ evaluation of the issuer’s prospects and risks in the early years following their IPO. One study documented substantial variation in the specificity of this disclosure and found that an increase in such specificity was associated with reduced IPO underpricing. Overall, the results suggested that IPOs with more specific use of proceeds disclosures allow investors to more aptly and confidently estimate secondary market stock performance.
It is likely that as the SEC rolls out additional disclosure requirements centered on items like climate change and cybersecurity to which issuers will be required to dedicate capital, issuers will be expected to provide even greater transparency to investors about the use of their offering proceeds.